Univercells Technologies’ product offering includes the unique scale-X single-use structured fixed-bed bioreactor for the intensified production of viruses used in cell and gene therapy, viral vaccines, and other therapeutics.
In addition, the company’s automated NevoLine Upstream platform incorporates industry-standard filtration to provide integrated up-and mid-stream processing capabilities in a single unit, driving productivity improvements.
Tod Carpenter, chairman, president and CEO of Donaldson, said: “The acquisition of Univercells Technologies represents an important next step in Donaldson’s life sciences strategy, as we continue to expand our product portfolio aimed at providing customers with a comprehensive, differentiated offering.”
“Univercells Technologies’ engineered systems provide close adjacencies with our previous life sciences acquisitions as well as with our growing organic product suite.”
Mathias Garny, CEO of Univercells Technologies, added: “We are extremely excited to join Donaldson as we grow our portfolio of best-in-class biomanufacturing platforms and increase our market penetration and related installed base of equipment.”
“Our technology, complemented by Donaldson’s filtration excellence and existing life sciences capabilities is part of a larger vision to bring end-to-end solutions to market for advanced therapies.”
Univercells Technologies was acquired for €136 million, subject to closing adjustments, from Gamma Biosciences and Univercells SA and will be a part of the Donaldson Life Sciences segment. Baker McKenzie acted as legal advisors to Donaldson.